The migraine drug, if approved, could compete very well against existing treatments such as Merck's Maxalt and GlaxoSmithKline's Imitrex.
FORBES: Puff Daddy
2.
For its human trials due to begin this summer Alexza has chosen a generic migraine drug that doesn't have the cardiovascular risks associated with Maxalt or Imitrex.